JRCT ID: jRCT1050230140
Registered date:03/12/2023
Retrospective study of anti-GD2 Immunotherapy
Basic Information
| Recruitment status | Recruiting |
|---|---|
| Health condition(s) or Problem(s) studied | Neuroblastoma |
| Date of first enrollment | 26/02/2024 |
| Target sample size | 120 |
| Countries of recruitment | |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | GD2 Immunotherapy Completion by Allogeneic Transplant History |
|---|---|
| Secondary Outcome | Adverse Events of GD2 Immunotherapy Drug Dose Changes in GD2 Immunotherapy Event free survival |
Key inclusion & exclusion criteria
| Age minimum | Not applicable |
|---|---|
| Age maximum | Not applicable |
| Gender | Both |
| Include criteria | Cases falling under (i) or (ii) (i) Cases with newly diagnosed neuroblastoma who was started GD2 immunotherapy between September 1, 2021 and December 31, 2022 within 1 year of transplantation (autologous or allogeneic) (ii) Cases with recurrent or relapsed neuroblastoma who was started GD2 immunotherapy between September 1, 2021 and December 31, 2022. |
| Exclude criteria | none |
Related Information
| Primary Sponsor | Nitani Chika |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Japan Agency for Medical Research and Development |
| Secondary ID(s) |
Contact
| Public contact | |
| Name | Chika Nitani |
| Address | 2-13-22 Miyakojima-hondori Miyakojima-ku Osaka Osaka Japan 534-0021 |
| Telephone | +81-6-6929-1221 |
| c-tanaka@med.osakacity-hp.or.jp | |
| Affiliation | Osaka City General Hospital |
| Scientific contact | |
| Name | Chika Nitani |
| Address | 2-13-22 Miyakojima-hondori Miyakojima-ku Osaka Osaka Japan 534-0021 |
| Telephone | +81-6-6929-1221 |
| c-tanaka@med.osakacity-hp.or.jp | |
| Affiliation | Osaka City General Hospital |